According to new research, people who have the inherited skin disorder known as Gorlin syndrome may be able to reduce their risk of developing skin cancer by taking the painkiller Celebrex (celecoxib). Gorlin syndrome causes people to develop hundreds or even thousands of cancerous lesions known as basal cell carcinomas. But in a new study, people who had this condition and who took the arthritis drug Celebrex had significantly fewer lesions after two years compared with patients who were given...
Read moreThe short answer is this: a person is 11 times more likely to develop schizophrenia if he or she has a relative with the disorder. It’s... Read more »
For as long as I can remember, I’ve had a spider phobia. I always dread the beginning of spring and fall because after a relatively... Read more »
When researchers, observers, and hypothesizers begin to make connections, it can become very interesting. I recently came across listings... Read more »
Fear, it seems, runs rampant in families with a loved one affected by Alzheimer's disease. Those caring for a declining parent or... Read more »
Reader's Question: My mother and father had skin cancer. Does this mean I will inherit skin cancer from my parents? Dr. Berman's... Read more »
Family history has been known to increase a child's risk of being allergy-prone, but a new study suggests that specific allergic triggers may be the... Read more »
Children inherit everything from freckles to hair color from their parents. But in addition to these physical appearance traits, there are also... Read more »
People who have the rare genetic condition known as homozygous familial hypercholesterolemia may be helped by the new drug mipomersen, new research... Read more »
The daughters of women who suffered from a severe form of morning sickness known as hyperemesis gravidarum are three times more likely to have the... Read more »
A new drug that helps people with an inherited form of high cholesterol is showing promise in clinical trials. The drug, AEGR-733, is being tested to... Read more »